Senior Vice President, and Chief Scientific Officer · CytomX Therapeutics, Inc. (CTMX)

Marcia Belvin

FY2023 is the first fiscal year CompBrief holds for Marcia Belvin as a named executive officer of CytomX Therapeutics; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$1,206,347

Salary $459,827Stock awards $402,250

2nd of 3 named executive officers at CytomX Therapeutics by FY2023 total.

3 named officers on file for CytomX Therapeutics, FY2023

Marcia Belvin’s pay file — $29

  • 1 fiscal year of pay, line by line
  • CTMX’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CytomX Therapeutics’s whole pay program stands against its peers

  • CytomX Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CTMX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 4, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Marcia Belvin’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Marcia Belvin compensation by year

CytomX Therapeutics Summary Compensation Table · the one fiscal year held
In US dollars, as CytomX Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$459,827
Bonus$0
Stock awards$402,250
Option awards$169,270
Non-equity incentive$170,000
Pension and deferred compensation$0
All other$5,000
Total$1,206,347

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CytomX Therapeutics, Inc. DEF 14A filed April 4, 2024, accession 0001140361-24-017969, and prior-year filings. Open the filing on EDGAR.

How this page was built: the CytomX Therapeutics, Inc. filed document, accession 0001140361-24-017969. Every figure is read from that document and cited to the page and table it appears in. Filed April 4, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
PSU75,000$116,250—
RSU60,000$93,000—
RSU40,000$62,000—
RSU16,875$26,156—
RSU11,250$17,438—
Option709—$7.13
Option8,334—$7.02
Option43,750—$7.85
Option13,750—$5.34
Option73,125—$4.13
Option75,000—$1.59
Option79,167—$2.59

Per the Outstanding Equity Awards at Fiscal Year-End table in CytomX Therapeutics, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

20 Form 4 lines since the FY2023 proxy (filed April 4, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-03-17Sale—31,492$6.42300,760
2026-02-02Grant or award—60,000$0.00332,252
2026-02-02Grant or award derivative—250,000$0.00250,000
2025-09-26Grant or award derivative—18,150$0.0018,150
2025-09-26Grant or award derivative—36,300$0.0036,300
2025-06-16Sale—13,884$2.69272,252
2025-06-13Exercise or conversion—37,500$0.00286,136
2025-06-13Exercise or conversion derivative—37,500$0.000

The 8 most recent of 20 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

CytomX Therapeutics’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
D. Sean A. McCarthyChief Executive Officer and Chairman of the Board of Directors$2,611,138
Marcia Belvin · this pageSenior Vice President, and Chief Scientific Officer$1,206,347
Jeff LandauSenior Vice President and Chief Business Officer$1,047,812

The full CytomX Therapeutics compensation record

free company brief

This page is one person within CytomX Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the CytomX Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CytomX Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Marcia Belvin's compensation dossier · One-time report. No refunds.